Laboratory Data Timeliness and Completeness Improves Following Implementation of an Electronic Laboratory Information System in C ôte d'Ivoire: Quasi-Experimental Study on 21 Clinical Laboratories From 2014 to 2020
CONCLUSIONS: These results demonstrate the value of electronic laboratory information systems in improving laboratory data quality and supporting evidence-based decision-making in health care. These findings highlight the importance of OpenELIS in Côte d'Ivoire and the potential for adoption in other low- and middle-income countries with similar health systems.PMID:38506899 | DOI:10.2196/50407 (Source: Cancer Control)
Source: Cancer Control - March 20, 2024 Category: Cancer & Oncology Authors: Yao He Yves-Rolland Kouabenan Paul Henri Assoa Nancy Puttkammer Bradley H Wagenaar Hong Xiao Stephen Gloyd Noah G Hoffman Pascal Komena N'zi Pierre Fourier Kamelan Casey Iiams-Hauser Adama Sanogo Pongathie Alain Kouakou Jan Flowers Nadine Abiola Natacha K Source Type: research

Revealing linguistic and verbal short-term and working memory abilities in people with severe aphasia
. (Source: Aphasiology)
Source: Aphasiology - March 20, 2024 Category: Speech-Language Pathology Authors: Wendy GreenspanSonia VieiraNadine Martina Department of Communication Sciences and Disorders, Temple University, Philadelphia, PA, USAb Department of Speech and Hearing Sciences, University of Washington, Seattle, WA, USA Source Type: research

News at a glance: ALS drug setback, controls on AI protein design, and rebuilding Ukrainian labs
DRUG DEVELOPMENT ALS drug comes up short in trial In a major setback for people suffering from amyotrophic lateral sclerosis (ALS), a drug approved in the United States and Canada in 2022 for the debilitating condition has failed in a 664-patient clinical trial, its maker, Amylyx Pharmaceuticals, said last week. Regulators approved the therapy, a combination of two compounds, despite their concerns that the evidence it provided a clinical benefit in a smaller study was weak. But treatment options for ALS are few. Amylyx says it will now spend 8 weeks consulting regulators and those affected by ALS...
Source: Science of Aging Knowledge Environment - March 14, 2024 Category: Geriatrics Source Type: research

Impact of Adjuvant Radiotherapy Setting on Quality-of-Life in Head and Neck Squamous Cell Carcinoma
CONCLUSION: This study revealed that HNSCC patients treated with radiation at AMCs reported significantly greater phys-QoL in their first-year post-treatment compared to those treated at CMCs, but soc-QoL did not differ significantly. Further observational studies are needed to explore potential factors, including treatment planning and cancer resource engagement, behind disparities between AMCs and CMCs.LEVEL OF EVIDENCE: Step 3 Laryngoscope, 2024.PMID:38436503 | DOI:10.1002/lary.31382 (Source: Health Physics)
Source: Health Physics - March 4, 2024 Category: Physics Authors: Rahul Alapati Sarah F Wagoner Amelia Lawrence Antonio Bon Nieves Atharva Desai Yelizaveta Shnayder Chelsea Hamill Kiran Kakarala Prakash Neupane Gregory Gan Kevin J Sykes Andr és M Bur Source Type: research

The impact of pregnancy and associated hormones on the pharmacokinetics of Δ9-tetrahydrocannabinol
. (Source: Expert Opinion on Drug Metabolism and Toxicology)
Source: Expert Opinion on Drug Metabolism and Toxicology - March 4, 2024 Category: Drugs & Pharmacology Authors: Aurora K. AuthementNina IsoherranenDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USA Source Type: research

Randomized Double-Blind Placebo-Controlled Study of Salivary Substitute with Enzymatic System for Xerostomia in Patients Irradiated in Head and Neck Region
This study aims to compare whether the use of a salivary substitute including an enzymatic system clinically reduces the intensity of xerostomia, as well as exploring the impact that this has on the quality of life, in patients who had received radiotherapy in the head and neck (HNC) region. Forty patients who had completed radiotherapy treatment within 6 months to 1 year previously were allocated into an Enzymatic Spray group (n = 21) or a Placebo arm (n = 19). It should be noted that two patients in the Placebo arm declined to participate during phase 2 of the study. All patients were randomized and used both products th...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Let ícia Pacheco Porangaba Fl ávio de Melo Garcia Ana Paula Alvarenga Antonio Rabelo Amanda Puche Andrade Fabio de Abreu Alves Antonio C ássio Assis Pellizzon Graziella Chagas Jaguar Source Type: research

Randomized Double-Blind Placebo-Controlled Study of Salivary Substitute with Enzymatic System for Xerostomia in Patients Irradiated in Head and Neck Region
This study aims to compare whether the use of a salivary substitute including an enzymatic system clinically reduces the intensity of xerostomia, as well as exploring the impact that this has on the quality of life, in patients who had received radiotherapy in the head and neck (HNC) region. Forty patients who had completed radiotherapy treatment within 6 months to 1 year previously were allocated into an Enzymatic Spray group (n = 21) or a Placebo arm (n = 19). It should be noted that two patients in the Placebo arm declined to participate during phase 2 of the study. All patients were randomized and used both products th...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Let ícia Pacheco Porangaba Fl ávio de Melo Garcia Ana Paula Alvarenga Antonio Rabelo Amanda Puche Andrade Fabio de Abreu Alves Antonio C ássio Assis Pellizzon Graziella Chagas Jaguar Source Type: research